Summary
41 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- Out of every 100 USD of revenue, 2,276 USD is left as free cash.
What to watch
- The company made a loss over the last 12 months.
- Revenue fell by 1.5% a year over the last 3 years.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 0.1% a year over 5 years. Over the last 3 years it fell by 1.5% a year. For the next fiscal year analysts expect revenue to grow by 4.9%.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $30.4B.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 9.63%
You receive $10.00 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.